Skip to content
NCI-H322
Tissue
肺
Disease
微創肺腺癌
Synonyms
H322, H-322, H322T, NCI-H322T, NCIH322T, NCI-322, NCIH322

Documents

NCI-H322

Cell line · Product number 305839

NCI-H322 is a human non-small cell lung cancer (NSCLC) cell line derived from an adult patient with a bronchioalveolar carcinoma, a histologic subtype of ...

US$395.00excl. tax and shipping
In stock
Lot
Recommended (freshest lot)
  • CoA
1

01General information

Description

NCI-H322 是一種源自成人患者的成人非小細胞肺癌(NSCLC)細胞系,該患者罹患支氣管肺泡癌,此為腺癌的一種組織學亞型。 該細胞系由美國國家癌症研究所(NCI)海軍醫學腫瘤學分部建立,作為一項全面性努力的一部分,旨在建立具有臨床註釋的肺癌模型,以供研究及治療開發之用。 NCI-H322 在體外呈現黏附性上皮形態,通常在標準細胞培養條件下,以添加 10% 胎牛血清的 RPMI-1640 培養基中維持生長。

NCI-H322 的分子分析顯示,其攜帶 KRAS 突變,該突變會透過 MAPK/ERK 及 PI3K/AKT 途徑促進致癌訊號傳導。 此突變使該細胞系對 EGFR 標靶療法產生抗藥性,使其適合用於針對 KRAS 驅動型肺腺癌的研究。此外,該細胞系在 EGFR 和 TP53 基因上均為野生型,為剖析 KRAS 依賴性腫瘤生物學提供了明確的遺傳背景。 其轉錄組與蛋白質組數據已納入《癌症細胞系百科全書》(CCLE)等大規模數據集,並在分析譜系特異性脆弱性及藥物反應模式方面發揮了重要作用。

NCI-H322 已被廣泛應用於藥理篩選和機制研究,以探索其對 MEK 抑制劑、PI3K 通路抑制劑及化療藥物的敏感性。 該細胞系在各項研究中表現一致,且突變譜有詳盡紀錄,使其成為 KRAS 突變型非小細胞肺癌(NSCLC)的寶貴臨床前模型,同時也是理解肺腺癌腫瘤異質性與藥物抗藥性研究中的關鍵參考。

Tissue
肺
Disease
微創肺腺癌
Synonyms
  • H322
  • H-322
  • H322T
  • NCI-H322T
  • NCIH322T
  • NCI-322
  • NCIH322

02Classification

Organism
Human
Sex
Male
Growth properties
Adherent
Biosafety level
1

03Characteristics

Cell type
俱樂部細胞
Doubling time
50

04Identifiers

Citation
NCI-H322(Cytion 型號 305839)
NCBI TaxID
9606
Cellosaurus
CVCL_1556

05Expression and susceptibility

Mutational profile
突變:TP53,簡單突變,p.Arg248Leu (c.743G>T),純合子 (PubMed=1311061, PubMed=1565469, PubMed=10536175, PubMed=20557307)。

06Handling and culture

Culture medium
RPMI 1640,含 2.0 mM 穩定谷氨醯胺,含 2.0 g/L NaHCO₃(Cytion 產品編號 820700a)
Incubation atmosphere

37°C,5% CO₂,加濕環境。

Supplements
在培養基中加入 10% 的胎牛血清(FBS)
Dissociation reagent
Accutase
Thawing and culturing
  1. Confirm that the vial remains deeply frozen upon delivery, as cells are shipped on dry ice to maintain optimal temperatures during transit.

  2. Upon receipt, either store the cryovial immediately at temperatures below -150°C to ensure the preservation of cellular integrity, or proceed to step 3 if immediate culturing is required.

  3. For immediate culturing, swiftly thaw the vial by immersing it in a 37°C water bath with clean water and an antimicrobial agent, agitating gently for 40-60 seconds until a small ice clump remains.

  4. Perform all subsequent steps under sterile conditions in a flow hood, disinfecting the cryovial with 70% ethanol before opening.

  5. Carefully open the disinfected vial and transfer the cell suspension into a 15 ml centrifuge tube containing 8 ml of room-temperature culture medium, mixing gently.

  6. Centrifuge the mixture at 300 x g for 3 minutes to separate the cells and carefully discard the supernatant containing residual freezing medium.

  7. Gently resuspend the cell pellet in 10 ml of fresh culture medium. For adherent cells, divide the suspension between two T25 culture flasks; for suspension cultures, transfer all the medium into one T25 flask to promote effective cell interaction and growth.

  8. Adhere to established subculture protocols for continued growth and maintenance of the cell line, ensuring reliable experimental outcomes.

07Quality control and cryopreservation

Sterility

透過基於 PCR 的檢測及基於發光原理的支原體檢測方法,排除支原體污染的可能性。

為確保無細菌、真菌或酵母菌污染,每日均會對細胞培養物進行目視檢查。

Freeze medium
作為冷凍保存培養基,我們使用完全生長培養基(含 FBS)+ 10% DMSO 以確保解凍後的存活率,或使用 CM-1 (Cytion 型號 800100),該培養基含有經優化的滲透保護劑和代謝穩定劑,可提升細胞恢復率並減輕冷凍誘導的壓力。
Storage conditions

若需長期保存,請將試管置於溫度約為 −150 至 −196 °C 的氣相液氮中。僅在轉移至液氮之前,可將試管暫時存放於 −80 °C 環境中,作為短期過渡步驟。

Shipping conditions

冷凍保存的細胞系會以乾冰冷藏,並裝於經驗證的隔熱包裝中,包裝內含有足夠的冷媒,以確保在運輸過程中溫度維持在約 −78 °C。收到貨物後,請立即檢查容器,並盡快將試管轉移至適當的儲存場所。

08Donor

Donor age
52年
Ethnicity
高加索人